KMT2AR
Clinical trials for KMT2AR explained in plain language.
Never miss a new study
Get alerted when new KMT2AR trials appear
Sign up with your email to follow new studies for KMT2AR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail takes aim at Hard-to-Treat leukemia
Disease control Recruiting nowThis early-stage trial is testing a new drug called ziftomenib combined with standard chemotherapy or another targeted drug for people with relapsed or treatment-resistant acute myeloid leukemia (AML) that has specific genetic changes. The main goal is to see if these combination…
Matched conditions: KMT2AR
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug cocktail aims to tackle tough leukemia
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called ziftomenib alongside standard treatments for acute myeloid leukemia (AML) in people with specific gene mutations. About 420 participants with newly diagnosed or relapsed AML will be assigned to one of three treatment a…
Matched conditions: KMT2AR
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC